A455cost benefit analysis and 3 BIAs. Key assessment criteria that the other studies did not meet were consideration of all relevant costs and execution of a sensitivity analysis. Of the best quality studies, 3 reported net economic benefits from implementing SEDs, at least in the base case analysis. ConClusions: Investment in SEDs generates economic benefits from savings in managing medical sharps injuries and their sequelae. Future economic evaluations need to carefully assess all important and pertinent costs to enable well-informed decision making about the implementation of SEDs in the health care workplace.

S91 based upon their anticipated budget impact and affordability, 100% were deemed low value. ConCluSionS: ICER reports have generally concluded that assessed therapies offer important clinical benefits but generally do not justify their economic impact. These reports currently do not influence coverage/pricing decisions but there is anecdotal evidence of insurers using these in negotiations. For example they were formally cited as part of Medicare Part B payment model reform discussions, indicating ICER reports may play a greater role in future reforms to US drug reimbursement as payers struggle to manage increasing costs.